L26/P-104 A multicenter, prospective sibling oocyte study revealed that a novel capacitation sperm technology improves embryo development in patients undergoing in vitro fertilization
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.440 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M. Gomez-Elias und 13 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does sperm preparation with a novel sperm capacitation technology improve blastocyst rate in conventional in vitro fertilization (IVF)? Summary answer A novel sperm capacitation technology increased blastocyst rates compared with standard sperm preparation, without affecting fertilization rates, in a prospective sibling oocyte IVF study. What is known already Sperm capacitation is critical for successful fertilization and early embryo development. A novel sperm preparation approach aimed at enhancing sperm function while preserving viability and acrosomal integrity has been previously developed and characterized. Using animal models and IVF cycles with donor oocytes, this approach has shown to improve embryo development and blastocyst yield. In addition, analyses performed on semen samples from infertile patients demonstrated enhanced sperm functional parameters without detrimental effects on DNA integrity or cell viability. However, its clinical utility in IVF cycles using autologous oocytes had not yet been established. Study design, size, duration Prospective, multicenter, sibling oocyte study including 41 couples (women aged 20–41 years and men aged 20–55) undergoing conventional IVF, attending 3 clinics between August 2023 and December 2025. Participants/materials, setting, methods Cumulus oocyte complexes (COCs) were divided into two groups and inseminated with sperm obtained after standard preparation protocols (Control) or HyperSperm (Treatment). Couples meeting predefined ovarian reserve and semen quality criteria were included. Fertilization and embryo development were assessed on D1 and D5/6, respectively. The primary outcome was blastocyst rate. Secondary outcomes included fertilization rate and embryo quality. Euploidy (PGT-A), and pregnancy outcomes were recorded. Wilcoxon signed-rank test with statistical significance at p < 0.05 was used. Main results and the role of chance A total of 598 COCs were retrieved and randomly allocated to Control (n = 297) and Treatment (n = 301) arms. After excluding immature oocytes on D1, fertilization rates were comparable between groups (192/268=71.6% vs. 180/249=72.3%, p = 0.86). However, the blastocyst rate per fertilized egg was higher in the Treatment group (92/192=47.9% vs. 100/180=55.6%, p = 0.0038), resulting in a greater number of blastocysts per cycle compared with Control, as was the utilizable blastocyst rate (77/192=40.1% vs. 88/180=48.9%, p = 0.0104). Although blastocyst quality distribution did not differ significantly between groups, the Treament arm showed a higher proportion of grade AA blastocysts (Gardner score) compared with Control. In a subset of embryos undergoing PGT-A, a higher euploidy rate was observed in the Treatment group, although this difference did not reach statistical significance. To date, 25 embryo transfers using Treated sperm-derived embryos resulted in 8 biochemical pregnancies, 5 confirmed clinical pregnancies, and 3 live births, with additional outcomes ongoing. Limitations, reasons for caution The study was not powered to detect differences in euploidy or pregnancy outcomes, and PGT-A was performed only in a subset of embryos. Wider implications of the findings These findings support a novel sperm capacitation technology as a sperm preparation strategy that can enhance blastocyst yield in conventional IVF cycles, potentially improving embryo availability for transfer without compromising fertilization. Larger studies are warranted to evaluate effects on chromosomal competence and clinical outcomes. Trial registration number Yes
Zitieren
APA
Gomez-Elias, M., Bisioli, C., Horton, M., Kopcow, L., Papayannis, M., Martino, E. D., Luque, G., Graf, C. B., Attie, M., Lavolpe, M., Carizza, C., Monserrat, V. T., Navall, E., & Buffone, M. (2026). L26/P-104 A multicenter, prospective sibling oocyte study revealed that a novel capacitation sperm technology improves embryo development in patients undergoing in vitro fertilization. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.440
Vancouver
Gomez-Elias M, Bisioli C, Horton M, Kopcow L, Papayannis M, Martino ED, et al. L26/P-104 A multicenter, prospective sibling oocyte study revealed that a novel capacitation sperm technology improves embryo development in patients undergoing in vitro fertilization. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.440
BibTeX
@article{GomezElias2026,
author = {Gomez-Elias, M. and Bisioli, C. and Horton, M. and Kopcow, L. and Papayannis, M. and Martino, E. De and Luque, G. and Graf, C. Baro and Attie, M. and Lavolpe, M. and Carizza, C. and Monserrat, V. Torres and Navall, E. and Buffone, M.},
title = {L26/P-104 A multicenter, prospective sibling oocyte study revealed that a novel capacitation sperm technology improves embryo development in patients undergoing in vitro fertilization},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.440}
}
EUVIMED